BeninTuberculosis profile
Population  2015 11 million
Estimates of TB burden*, 2015 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 1 (0.62–1.6) 9.5 (5.7–14)
Mortality (HIV+TB only) 0.29 (0.11–0.56) 2.7 (1–5.2)
Incidence  (includes HIV+TB) 6.6 (4.2–9.4) 60 (39–86)
Incidence (HIV+TB only) 1 (0.64–1.4) 9.2 (5.9–13)
Incidence (MDR/RR-TB)** 0.1 (<0.01–0.2) 0.92 (0.07–1.8)
Estimated TB incidence by age and sex (thousands)*, 2015
  0-14 years > 14 years Total
Females 0.41 (0.22–0.61) 2 (0.72–3.3) 2.4 (0.94–3.9)
Males 0.32 (0.19–0.45) 3.8 (2.6–5) 4.1 (2.8–5.4)
Total 0.74 (0.47–1) 5.8 (4.4–7.2) 6.6 (4.2–9.4)
TB case notifications, 2015  
Total cases notified 4 092
Total new and relapse 3 985
          - % tested with rapid diagnostics at time of diagnosis  
          - % with known HIV status 101%
          - % pulmonary 91%
          - % bacteriologically confirmed among pulmonary 91%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2015 61% (43–94)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2015 0.21 (0.12–0.36)
TB/HIV care in new and relapse TB patients, 2015 Number (%)
Patients with known HIV-status who are HIV-positive 613 15%
          - on antiretroviral therapy 531 87%
Drug-resistant TB care, 2015 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  61
(11–110)
Estimated % of TB cases with MDR/RR-TB 1.2% (0–2.6) 8.1% (4.6–13)  
% notified tested for rifampicin resistance 8% 101% 594
MDR/RR-TB cases tested for resistance to second-line drugs   23
Laboratory-confirmed cases MDR/RR-TB: 23, XDR-TB: 0
Patients started on treatment **** MDR/RR-TB: 19, XDR-TB: 0
Treatment success rate and cohort size Success Cohort
New cases registered in 2014 89% 3 749
Previously treated cases registered in 2014 78% 223
HIV-positive TB cases, all types, registered in 2014    
MDR/RR-TB cases started on second-line treatment in 2013 93% 14
XDR-TB cases started on second-line treatment in 2013    
TB preventive treatment, 2015  
% of HIV-positive people (newly enrolled in care) on preventive treatment  
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
49% (45–53)
TB financing, 2016  
National TB budget (US$ millions) 6.8
Funding source: 10% domestic, 56% international, 34% unfunded
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2015
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New cases
   Previously treated cases
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-12-08 Data: www.who.int/tb/data